8-Bromo-7-ma-2-ynyl-3-methyl-1- (4-methyl-quinazolin-2-ylmethyl) -3

Iji nyochaa linagliptin dị adị na isi ya etiti 8-bromo-7- (2-butynyl) -3,7-dihydro-3-methyl-1-[(4-methyl -2-quinazolinyl) methyl) -1H-purine- 2,6-dione (11) usoro njikọ, chọta ụzọ sịntetik dabara adaba maka mmepụta mmepụta ihe.Usoro: chịkọta ụzọ dị iche iche sịntetik.Nsonaazụ na nkwubi okwu: Ụzọ 2.2 nwere usoro dị mfe na ọnụ ala dị ala, nke dabara adaba maka mmepụta mmepụta ihe.

8-bromo-3,7-dihydro-3-methyl-1H-purine-2,6-dione bụ isi etiti na njikọ nke ọgwụ hypoglycemic linagliptin.Njikọ nke 1 na-eji methyl urea na cyanoacetic acid dị ka ihe mmalite, ma na-enweta mmeghachi omume isii nke condensation, cyclization, nitrosation, mbelata, cyclization, na bromine na ngụkọta nke 46.3%.1HNMR kwadoro nhazi nke ndị etiti niile.

Ihe mepụtara ugbu a metụtara usoro nkwadebe dị mfe nke linagliptin dị ọcha.Quinazoline, isi ihe dị n'etiti maka nkwadebe otu ite nke linagliptin 8 bromo 7 (2 butyne 1 base) 3,7 dihydro 3 methyl 1 [(4 methyl 2 quinazolinyl) methyl] 1H Purine 2,6 dione, nke etiti bụ nke kewara. filtration, wee meghachi omume na (R) 3 aminopiperidine dihydrochloride iji nweta ngwọta nwere linagliptin.Mgbe emechara ihe ngwọta nwere linagliptin ọzọ, ngwaahịa Deliraliptin dị ọcha.Nkwadebe nke isi etiti nke ihe a na-emepụta ugbu a na-agbaso usoro otu ite, nke dị mma iji rụọ ọrụ ma na-eme ka mkpụrụ dị mma.Mgbe ekewasịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsịsị akwụkwọ), a na-emeghachi ya na (R)3 aminopiperidine dihydrochloride (R) 3 aminopiperidine dihydrochloride, si otú ahụ nweta linagliptin dị ọcha na-ezutekwa mmepụta na nkwupụta nke ụlọ ọrụ ọgwụ ruo oke.